- STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancerA lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.STAT · 1mo ago↗ source
- STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study findsBy doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.STAT · 1mo ago↗ source
- STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDAASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.STAT · 1mo ago